Chugai Pharmaceutical Co., Ltd. (CHGCF)
Chugai Pharmaceutical Co., Ltd.
2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp
Sector(es): Healthcare
Industria: Drug Manufacturers - General
Empleados a tiempo completo: 7,604
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Osamu Okuda | President, CEO & Representative Director | 1.42M | N/D | 1963 |
| Mr. Iwaaki Taniguchi | Executive VP, Head of Finance Supervisory Div., CFO & Director | N/D | N/D | 1967 |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | N/D | N/D | N/D |
| Mr. Masayoshi Higuchi | VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept. | N/D | N/D | N/D |
| Mr. Shinji Hidaka | Executive Vice President | N/D | N/D | N/D |
| Mr. Junichi Ebihara | Executive Vice President | N/D | N/D | N/D |
| Dr. Yoshiaki Ohashi | SVP & Full-time Audit Supervisory Board Member | N/D | N/D | 1960 |
| Mr. Tetsuya Yamaguchi | Executive VP & Head of PHC Solution Unit | N/D | N/D | N/D |
| Mr. Yoshiyuki Yano | Executive Vice President | N/D | N/D | N/D |
| Dr. Shigehiro Yamada Ph.D. | Head of Sustainability Department and Full-Time Audit & Supervisory Board Member | N/D | N/D | 1964 |
Descripción
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Gestión corporativa
La calificación ISS Governance QuickScore de Chugai Pharmaceutical Co., Ltd. a partir del 1 de mayo de 2024 es 5. Las puntuaciones principales son Auditoría: 1; Junta: 7; Derechos del accionista: 2; Compensación: 1.
